
# Achievement of the ABC target among Canadians with type 2 diabetes: data from the CHMS A. Marcotte-Chénard<sup>1,2</sup>, R. Maréchal<sup>1,2</sup>, A. Ghachem<sup>3</sup>, A. Cohen<sup>4</sup>, E. Riesco<sup>1,2</sup>

<sup>1</sup> Research Center on Aging CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, <sup>2</sup> Faculty of physical activity science, University of Sherbrooke, Sherbrooke, QC, Canada, <sup>3</sup> Institute for Excellence in Health and Social Services (INESS), Montreal, QC, Canada, <sup>4</sup> Columbia University, New York, NY, USA.

### Introduction



### Objectives

1) The main objective of this study was to update the prevalence trend of T2D in Canada from 2007 to 2017 and the proportion of individuals meeting the ABC during that period.

2) The secondary objective was to investigate how sedentary behaviors, physical activity duration and intensity may explain the achievement of ABC.





**Canadian Health** Measures Survey (96-97%)

Adults  $\geq$  18 years of age **Excluding criteria** Pregnant female Living in the Canadian territories Living in Indigenous reserves Members of the Canadian Forces

	Non-T2D	T2D
	<b>N= 24 126 785</b> (93.7%)	N= 1 603 472 (6.3%)
Age (years)	44.4 ± 15.9	60.2 ± 11.1 +
Sex (men; %)	49.4 [49.4 - 49.5]	57.6 [57.5 - 57.7] †
BMI (kg/m²)	27.1 ± 5.6	31.4 ± 7.1 †
Non hispanic white (%)	80.5 [80.5-80.5]	80.3 [80.2-80.3]
Regular smoker (%)	20.3 [20.3-20.4]	19.5 [19.4-19.6]
Regular drinker (%)	69.5 [69.5-69.6]	48.9 [48.8-48.9] †
A1c (%)	$5.44 \pm 0.46$	7.39 ± 1.56 †
Fasting glucose (mmol/L)	$5.03 \pm 0.68$	8.45 ± 3.34 +
Fasting insulin (mmol/L)	74.7 ± 63.4	144.5 ± 156.0 †
HDL cholesterol (mmol/L)	$1.41 \pm 0.41$	1.19 ± 0.35 +
LDL cholesterol (mmol/L)	$2.85 \pm 0.90$	2.31 ± 1.00 +
SBP (mmHg)	$112.0 \pm 15.3$	120.7 ± 16.7 †
DBP (mmHg)	72.0 ± 9.6	72.2 ± 9.8
Medication		
Hypoglycemic (%)	0.80 [0.80-0.81]	78.64 [78.57-78.70] †
Antihypertensive (%)	19.32 [19.30-19.34]	69.8 [69.73-69.89] †
Hypolipidemic (%)	12.50 [12.48-12.51]	63.19 [63.09-63.26]†
*ABC (%)	0.385 [0.382-0.389]	42.9 [42.86-43.03] +
Table 1. Participant's	characteristics.	

Data are presented mean ± SD or in percentage (%). T2D= type 2 diabetes; BMI= body mass index; A1c= glycated hemoglobin; HDL= high-density lipoprotein; LDL= low-density lipoprotein; SBP= systolic blood pressure; DBP= diastolic blood pressure. † significant difference between T2D and non-T2D (p= 0.01).

	A1c (<7%)	LDL-C (<2.0 mmol/L)	BP (<130/80 mmHg)	ABC
Non-T2D (%)	99.3	15.9	76.1	13.5
*Medication (%)	0.8	12.5	19.3	0.4
T2D (%)	51.3	42.0	64.4	14.1
*Medication (%)	78.6	63.2	69.8	42.9


Table 3. Prevalence of Canadians, with and without type 2 diabetes, achieving the ABC target (10-year estimate).

Data are presented in percentage and weighted to represent the Canadian Population.

) The prevalence of T2D has increased from 2007 to 2017 in the Canadian population, with a considerable number of undiagnosed patients. Only a small proportion of individuals with T2D meet the ABC recommendations, but fortunately, this prevalence has increased over the years

2) Active individuals who perform more than 142 min per week of MVPA are more likely to reach the ABC target. In addition to physical activity, other important factors such as BMI and the use of medication should also be considered as modifiable contributing factors.

### Methods




### Questionnaire Yes or No


	T2D diagnostic	T2D A1c/Glucose	T2D overall
Cycle 1 2007-2009)	3.72 %	1.08 %	4.80 %
Cycle 2 2010-2011)	4.94 %	1.58 %	6.52 %
Cycle 3 2012-2013)	5.11 %	0.32 %*	5.43 %
Cycle 4 2014-2015)	4.92 %	0.74 %*	5.66 %
Cycle 5 2016-2017)	6.38 %	2.00 %	8.38 %
Cycle 1-5 2007-2017)	5.06 %	1.18 %	6.23 %

Results


### Table 2. Prevalence of T2D in Canada from 2007-2009 to 2016-2017 in the adult population.

Data are presented in percentage and weighted to represent the Canadian Population (individual and combine; 1-5).\*One should be cautious when interpreting the undiagnosed prevalence of T2D in the cycle 3 and 4 considering the smaller sample size for fasting variable.





### Conclusion



_				
	A1c (<7%)	LDL (<2.0 mmol/L)	BP (<130/80 mmHg)	ABC total
	49.8 %	19.5 %	66.0 %	11.5 %
	46.9 %	32.0 %	63.8 %	11.3 %
	58.1 %	48.4 %	73.0 %	16.8 %
	56.1 %	51.1 %	56.2 %	14.9 %
	48.6 %	39.3 %	63.3 %	14.8 %

### Table 4. Prevalence of type 2 diabetes individuals meeting the ABC target and its component in Canada from 2007 to 2017.


Data are presented in percentage and weighted to represent the Canadian Population.

**References: 1-** Cho et a. 2018 2- Diabetes Canada. 2020 3- Baena-Díez et al. 2016 **4-** Stone et al. 2018 **5-** Braga et al., 2010 6- Leither et al., 2013 **7-** Sigal et al., 2018

Image are from Canva and Biorender

More information about this project





## Université de Sherbrooke

### ACUTE NK CELLS RESPONSE TO DIFFERENT AEROBIC EXERCISE MODALITIES IN METASTATIC CANCER PATIENTS **UNDERGOING CHEMOTHERAPY Parent-Roberge H<sup>1,2</sup>**, Fontvieille A1,2, Tai, LH<sup>3,4</sup>, Pavic M<sup>3,4</sup>, Fulop T<sup>1,3</sup>, Riesco E<sup>1,2</sup>.


Aerobic exercise acutely elicits a lymphocytosis followed by a rapid decrease in lymphocyte blood counts in the subsequent hours, mainly reflecting their tissular redeployment. CD56<sup>dim</sup>CD16<sup>+</sup> cytotoxic NK (cNK) cells strongly respond to this exercise-induced redeployment, which might promote their tumoral infiltration following each exercise session, and thus represent a potential adjuvant strategy to existing anticancer therapies. However, this promising immune response has not been studied in cancer therapies. However, this promising immune response has not been studied in cancer therapies. aerobic exercise (MOD) session and a work-matched high-intensity interval exercise (HIIE) session in cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performed a MOD and a work-matched HIIE in a block-randomized order, 24 hours before a chemotherapy for a metastatic cancer performance a metastatic cancer perfor treatment. Peripheral blood mononuclear cells were isolated before, immediately after and 1h after exercise. Flow cytometry and complete blood counts were used to enumerate NK cell subsets (CD56, CD16) and their surface expression of the following markers: NKG2D, CD158a, CD57, PD-1, TIM-3, CXCR3, CXCR4 and CCR2. Results: Immediately following MOD, cNK cells levels significantly increased relative to pre-exercise (+1.91±1.37-fold, p<0.001), back to pre-exercise (+1.91±1.37-fold, p<0.001), back to pre-exercise (-0.65±0.12-fold, p<0.001), back to pre-exercise (-0.65±0.12-fold, p<0.001), back to pre-exercise (-0.65±0.12-fold, p<0.001), back to pre-exercise (+1.91±1.37-fold, p<0.001), back to pre-exercise (-0.65±0.12-fold, p<0.001), back to pre-ex (all p<0.001). HIE elicited an effect of similar magnitude on each of these subsets, with no difference between trials (all p $\ge 0.38$ ). However, strong correlations were found between the cNK cells fold-decrease 1h-post HIE and power output (r =0.86, p=0.002). Conclusion: both trials induced a redeployment of cNK cells exhibiting tumor migration and cytotoxic potentially fitness-dependent.

### Background

### Could the cytotoxic NK (cNK) cells acute response to exercise promote anti-tumor immunity in cancer patients?

<u>1) During exercise</u>: Strong  $\beta_2$ -adrenergic induce blood mobilisation of cNK cells 2

2) After exercise cessation: Rapid vascular egress, dependent upon catecholamines and cortisol, induce inflammatory chemokine receptors expression<sup>2</sup>



3) Post-exercise harvested cNK cells:  $\uparrow$  cytotoxic activity against various cancer cell lines (*in vitro* cytotoxic assays)<sup>3</sup>


Could moderate continuous aerobic (MOD) or high-intensity intervals (HIIE) exercise mobilize cNK cells with tumor infiltration and cytolysis potential in cancer patients?<sup>4</sup>

### **Objective**

To characterise the acute cNK cell response to a MOD and a work-matched HIE session in metastatic cancer patients currently being treated by chemotherapy

References 1) Graff et al. (2018). Brain. Behav. Immun., 74 (August), 143–153.; 2) Peake et al. (2017). Journal of Applied Physiology, 122(5), 1077–1087.; 3) Bigley et al. (2014). Brain, Behavior, and Immunity, 39, 160–171.; 4) Idorn & Hojman (2016). Trends in Molecular Medicine, 22(7), 565–577.


1 Centre de recherche sur le vieillissement, CIUSSS de l'Estrie - CHUS; 2 Faculté de sciences de la santé, Université de Sherbrooke; 4 Centre de recherche du CHUS.



**Samples processing :** 


1) PBMCs were isolated using gradient centrifugation and kept in liquid nitrogen upon analysis

2) Differential leukocyte count (for blood count computation of each gated subset)




### Flow cytometry analysis :

NK cells : CD3<sup>-</sup>CD56<sup>+</sup> lymphocytes




CD3 – APC-H7


**Evaluated for expression of** Cytotoxic NK cells : CD56<sup>dim</sup>CD16<sup>+</sup> the following markers:



1 min high intensity (200 % MOD)

2 min irecovery (50% MOD)







Differentiation markers: CD57, CD158a, NKG2D


Chemokine receptors : CXCR3, CXCR4, CCR2

Immune checkpoints : TIM-3, PD-1





2) The acute cNK cell mobilisation and egress were strongly correlated with exercise intensity, but only following HIIE.



1) Both MOD and HIIE session can mobilize highly differentiated cytotoxic NK cells with a phenotype suggestive of a good tumor homing potential in metastatic cancer patients undergoing chemotherapy.

2) The NK cells response to MOD and HIIE might be differently driven by exercise intensity.

3) These results will guide future longitudinal exercise trials to investigate the clinical benefits of different aerobic exercise training modalities in the cancer population.



### Results

1) cNK cells expressing CD57, NKG2D, the immune checkpoint TIM-3 and the chemokine receptor CXCR3 were the most exercise responsive subsets, with no difference between trials.


Data are presented as mean  $\pm$  standard deviation. g-values = Benjamini-Hotchberg adjusted p-values

### **Discussion/Conclusion**






# WITH HYPERTENSION AND TYPE 2 DIABETES








# (HIIT)<sup>4</sup>



- physical activity)



S	

(n=10/15)	
$69.8\pm4.94$	
$33.28\pm5.96$	
$108.42 \pm 12.47$	
$13.1 \pm 6.88$	
$17.48\pm3.48$	
$6.7\pm0.78$	
$6.5 \pm 1.18$	
$123 \pm 9$	
$77 \pm 5$	



Université de Sherbrooke




### INTRODUCTION

- Glucose tolerance<sup>1</sup> (GT), muscle mass<sup>2</sup> (MM/FFM) strength<sup>2</sup> are thought to decline in and postmenopausal women (PMW)
- Exercise guidelines for healthy aging include resistance training (RT) with heavy weights and moderate-to-low repetitions (HWLR) with the aim of increasing MM<sup>3</sup>
- RT with low weights and high repetitions (LWHR), has also shown to be efficient for muscle adaptations<sup>4</sup>
- The magnitude of muscle acute response and adaptations to RT has been suggested to depend on training load (total weight lifted ; TWL)<sup>5</sup>

## **AIMS & HYPOTHESES**

- The relationship between FFM and GT is unclear and has never been tested in response to acute RT in PMW.<sup>6</sup>
- It is unknown if acute RT can enhance acute GT and which RT protocol has the greatest potential in PMW.

### METHODS



12 healthy PMW (50-72y)


- Non smoker, light alcohol drinker
- <75min structured exercice/week
- New to resistance training






Rest for 60 minutes

Condition 2: HWLR



3 x 10 reps 75-80% 1RM





2 x 25 reps 50-55% 1RM

# **PROTOCOL AND LOAD IN POSTMENOPAUSAL WOMEN?**

### FIG. 1. EXPERIMENTAL DESIGN <mark>派</mark>会 Experimental ፞፞ጞ condition (Control, **Pre-experimentation** HWLR or LWHR) 7.45 8.00 9.30 10.00 11.00 Time (hours) Glucose load (75g) Blood draw



FFM was measured with dual x-ray absoptiometry (iDXA, GE Healthcare)

Standardized

breakfast


Blood glucose was determined in each blood sample with a hexokinase method (Dimension, Vista System). Glucose fold change was calculated as the difference between pre and post glucose/pre-exercise glucose


VO<sub>2</sub>peak was measured with a breath-by-breath technique using a metabolic cart (Medisoft Expair)


### RESULTS

TABLE 1. PARTICIPANTS CHARACTERISTICS (n=12)		TABLE 2. TR	RAINING PAR	AMETERS
Age (years)	65.9 ± 5.6		HWLR (3 x	LWHR (2 x 25
Weight (kg)	64.3 ± 9.3			reps @ 50- 55% 1RM)
Waist circumference (cm)	92.4 ± 10.3			
BMI (kg/m²)	24.3 ± 3.5	TWL (lb)	8573.2 ± 2297.9	9464.1 ± 2521.2*
Fat-free mass (kg)	37.9 ± 3.6			E E L O O
Fat mass (kg)	24.0 ± 7.4	sRPE (/10)	6,3 ± 2,4	5,5 ± 2,3
Vo <sub>2</sub> peak (ml/kg/min)	22.3 ± 6.5	*Significantly dif	ferent from HW	'LR (p≤0,001)
Fasting glucose (mmol/L)	4.9 ± 0.2			
2-h glucose (mmol/L)	$7.4 \pm 2.0$			
Glucose AUC (mmol/L*120min)	973.7 ± 183.7			

Results are presented as average  $\pm$  SD







### J. Paquin,<sup>1,2</sup> P. St-Martin,<sup>1,2</sup> M. Brochu,<sup>1,2</sup> et I.J. Dionne.<sup>1,2</sup>

<sup>1</sup>Faculté des sciences de l'activité physique, Université de Sherbrooke, 2500 boul. de l'Université, Sherbrooke, QC J1K 2R1, Canada <sup>2</sup>Centre de recherche sur le vieillissement, CIUSSS de l'Estrie-CHUS, 1036 Rue Belvédère S, Sherbrooke, QC J1H 4C4, Canada

TABLE 3. CORRELATION MATRIX FOR SELECTED EXERCISE, BODY COMPOSITION AND GLUCOSE METABOLISM PARAMETERS					ION AND	
	Total MM	Lower body 1RM	TWL - HWLR	TWL - LWHR	Glucose foldchange - HWLR	Glucose foldchange - LWHR
Lower body 1RM	0,51‡					
TWL - HWLR	0,34	0,95*				
TWL - LWHR	0,46	0,94*				
Glucose foldchange - HWLR	0,47	0,16	-0,01	0,08		
Glucose foldchange - LWHR	0,16	0,68*	0,75*	0,63*		
Glucose AUC - Control	- 0,54‡	-0,04	-0,02	-0,08	-0,45	-0,26

Statistically significant ( $*p \le 0.05$ ) and almost statistically significant result (p = 0.07) are shown in bold.

### **IS HEART RATE A RELIABLE TEST TERMINATION CRITERION WITH INDIVIDUALS UNDERGOING CHEMOTHERAPY FOR METASTATIC CANCER?** L. Poirier<sup>1</sup>, H. Parent-Roberge<sup>1</sup>, A. Fontvieille<sup>1</sup>, M. Pavic<sup>2,3</sup> and E. Riesco<sup>1,3</sup> 1. Faculty of physical activity sciences, University of Sherbrooke, and Research Centre on Aging of CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada; 2. Faculty of medicine and health sciences,


BACKGROUND: There are feasibility and acceptability issues in prescribing exercise intensity using cardiopulmonary exercise test or a predicted % HRmax or %HR reserve (HRR) and perceived exertion (PE) as stopping criteria. However, the HRmax prediction and the presence of autonomic dysfunction in cancer patients may increase the heterogeneity regarding test effectively translates into a proper intensity during subsequent exercise sessions in cancer patients undergoing in cancer patients undergoing. chemotherapy. **METHODS**: Eleven individuals (57±7 years) undergoing treatments for metastatic cancer performed a modified YMCA (mYMCA) test. Participants were separated into two groups: REACH (n=6) who terminated the test without reaching the THR. The following measures were collected during the mYMCA and two different exercise sessions (high-intensity interval exercise [HIIE] and moderate-intensity exercise [MICE]): HR, PE (Borg CR10 scale), capillary lactate (La<sup>-</sup>) and power output. RESULTS: During the last complete stage of the mYMCA, despite the difference in  $\Delta$ bpm from THR between groups (REACH: 6 [4] bpm, 74 [12] %HRR; No-REACH: 21 [13] bpm, 60 [14] %HRR; p=0.002), there was no group difference for PE (REACH: 7 [3], No-REACH: 8 [2]; p=0.08) and La<sup>-</sup> (HIE: 4.9 [1.7] vs. 4.4 [3.2]; p=0.37; MICE: 2.8 [1.6] vs. 3.7 [2.1]; p=0.43) nor for PE at the end of HIE (5 [4] vs. 6 [6]; p=0.27). CONCLUSION: These results suggest that using HR as the only stopping criterion for a submaximal test may lead some cancer patients to exceed the targeted submaximal test may lead some cancer patients to exceed the targeted submaximal test.

## Introduction


UDS

Université de

Sherbrooke



as a stopping criterion during a



REFERENCES: 1) Liguori, et al., Wolters Kluwer Health, 2018; 2) Taylor, J. L., et al. (2013). Eur J Prev Physiol 2: 442-467; 4) Dalleck, L., et al. (2016). Journal of Fitness Research, 5(3), 15-27;

# University of Sherbrooke, Sherbrooke, QC, Canada; 3. Cancer Research Institute, University of Sherbrooke, Sherbrooke, QC, Canada.

### Methods

		<b>Measures</b>
		Lactate [La <sup>-</sup> ], HR, R
90-100	100	Ex
65 W	45 W	
55 W	40 W	High-intensity exerci
		10 x 1 min @ 100% e
		PO, with 2 min rest
Mor		1) REAC
		Groups 2) No-RE



Supported by the Sylvain Poissant Foundation.